Apomorphine in the treatment of Parkinson disease and other movement disorders

被引:0
作者
Gunzler, Steven A. [1 ]
机构
[1] Case Western Reserve Univ, Sch Med, Univ Hosp,Movement Disorders Ctr, Case Med Ctr,Neurol Inst, Cleveland, OH 44106 USA
关键词
apomorphine; dopamine agonist; movement disorders; Parkinson disease; RESTLESS LEGS SYNDROME; DEEP BRAIN-STIMULATION; NEUROLEPTIC MALIGNANT SYNDROME; TERM-FOLLOW-UP; SUBCUTANEOUS APOMORPHINE; DOUBLE-BLIND; MOTOR FLUCTUATIONS; HUNTINGTONS-CHOREA; L-DOPA; DOPAMINERGIC RESPONSIVENESS;
D O I
10.1517/14656560902828344
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Apomorphine, a medication that has been studied intensively over the years, is available in the US as intermittent subcutaneous injections for treatment of 'off' motor states in Parkinson disease. Objective: The clinical literature is summarized with particular focus on randomized controlled studies of apomorphine in the treatment of Parkinson disease. Methods: After reviewing the pharmacologic properties of apomorphine, the English language literature is summarized with particular attention on articles resulting from a Medline search of apomorphine and Parkinson disease limited to randomized controlled studies. Other formulations and indications for treatment of movement disorders are also discussed. Results/conclusion: Subcutaneous apomorphine is well tolerated when co-administered with trimethobenzamide or domperidone premedication. it has a unique efficacy as a 'rescue' medication owing to its rapid onset of action. Subcutaneous infusion, although not an approved route of administration in the US, provides more continuous dopaminergic stimulation and, therefore, ameliorates dyskinesia and motor fluctuations.
引用
收藏
页码:1027 / 1038
页数:12
相关论文
共 50 条
  • [1] Apomorphine in the Treatment of Parkinson's Disease
    Ozkan, Serhat
    Erer, Sevda
    Elibol, Bulent
    Ozkaynak, Sehur Sibel
    Cakmur, Raif
    Akbostanci, Muhittin Cenk
    Hanagasi, Hasmet
    Dogu, Okan
    TURKISH JOURNAL OF NEUROLOGY, 2021, 27 (04) : 358 - 365
  • [2] Apomorphine hydrochloride for the treatment of Parkinson's disease
    Unti, Elisa
    Ceravolo, Roberto
    Bonuccelli, Ubaldo
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2015, 15 (07) : 723 - 732
  • [3] Amantadine in the treatment of Parkinson's disease and other movement disorders
    Rascol, Olivier
    Fabbri, Margherita
    Poewe, Werner
    LANCET NEUROLOGY, 2021, 20 (12) : 1048 - 1056
  • [4] Effective Delivery of Apomorphine in the Management of Parkinson Disease: Practical Considerations for Clinicians and Parkinson Nurses
    Bhidayasiri, Roongroj
    Chaudhuri, K. Ray
    LeWitt, Peter
    Martin, Anne
    Boonpang, Kamolwan
    van Laar, Teus
    CLINICAL NEUROPHARMACOLOGY, 2015, 38 (03) : 89 - 103
  • [5] Deep brain stimulation for Parkinson's disease and other movement disorders
    Kalia, Suneil K.
    Sankar, Tejas
    Lozano, Andres M.
    CURRENT OPINION IN NEUROLOGY, 2013, 26 (04) : 374 - 380
  • [6] Apomorphine Injection Therapy for Parkinson's Disease
    Odin, P.
    Bilsing, A.
    Durner, J.
    Honig, H.
    AKTUELLE NEUROLOGIE, 2011, 38 : S11 - S16
  • [7] Sublingual apomorphine in the treatment of Parkinson's disease
    Kassubek, Jan
    Jost, Wolfgang H.
    Schwarz, Johannes
    JOURNAL OF NEURAL TRANSMISSION, 2024, 131 (10) : 1209 - 1216
  • [8] Apomorphine in advanced Parkinson disease
    Bogucki, Andrzej
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2013, 47 (05) : 476 - 483
  • [9] Role of Apomorphine in the Treatment of Parkinson's Disease
    Boyle, Allison
    Ondo, William
    CNS DRUGS, 2015, 29 (02) : 83 - 89
  • [10] Transcranial direct current stimulation as treatment for Parkinson's disease and other movement disorders
    Ferrucci, Roberta
    Mameli, Francesca
    Ruggiero, Fabiana
    Priori, Alberto
    BASAL GANGLIA, 2016, 6 (01) : 53 - 61